Alterity Therapeutics (ATHE) vs Telomir Pharmaceuticals (TELO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Alterity Therapeutics (ATHE) has outperformed Telomir Pharmaceuticals (TELO) over the past year, losing 56.7% versus a loss of 71.6%. Alterity Therapeutics is the larger company by market cap ($29.0 million vs $26.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATHE | TELO |
|---|---|---|
| Share price | $1.52 | $0.364 |
| Market cap | $29.02M | $26.82M |
| 1-day change | -8.16% | -17.24% |
| YTD return | -50.65% | -72.63% |
| 1-year return | -56.70% | -71.56% |
| 5-year return | -85.38% | — |
| EPS (TTM) | $-0.90 | $-0.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-10.41M |
| 52-week high | $5.89 | $1.58 |
| 52-week low | $1.52 | $0.353 |
| Distance from 52-week high | -74.19% | -76.96% |
| Analyst consensus | none | none |
| Avg. price target upside | +771.71% | +998.90% |
| Average volume | 89.63K | 126.14K |
| Shares outstanding | 19.09M | 73.68M |
| Employees | 11 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ATHE has outperformed TELO by 14.9 percentage points over the past year.
About Alterity Therapeutics
ATHE stock →Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees
About Telomir Pharmaceuticals
TELO stock →Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria.
Health Care · Biotechnology: Pharmaceutical Preparations
ATHE vs TELO FAQ
Which is bigger, Alterity Therapeutics or Telomir Pharmaceuticals?
Alterity Therapeutics (ATHE) is larger, with a market capitalization of $29.02M compared with $26.82M for Telomir Pharmaceuticals (TELO).
Which stock has performed better over the past year, ATHE or TELO?
ATHE returned -56.70% over the past 12 months, compared with -71.56% for TELO (price return, excluding dividends). Past performance does not predict future results.
Are Alterity Therapeutics and Telomir Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.